“We are increasing our investment in vaccines, and we will develop a seasonal flu vaccine, given the unmet need for highly effective vaccines,” CEO Stephane Bancel said in a news release.
The drugmaker said vaccines typically reduce the risk of getting the flu by 40 percent to 60 percent and that high-risk groups would benefit from a flu shot with higher efficacy.
Between 9 million and 45 million people in the U.S. have died of the flu annually since 2010, according to the CDC.
Read the full news release here.
More articles on pharmacy:
Drug costs surge faster than any other medical good or service, data shows
Eli Lilly, Amgen partner to make Lilly’s COVID-19 antibody drug
Moderna will know if COVID-19 vaccine is effective in November, CEO says
